zelboraf造句

• In August 2011, the U . S . Food and Drug Administration ( FDA ) approved the drug vemurafenib ( Zelboraf ) for metastatic melanoma patients who test positive for a specific gene mutation.
• In November 2015, the U . S . Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib ( Zelboraf ).